oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000-2011
Section of Hematology and Coagulation, Sahlgrenska University Hospital, Gothenburg, Sweden; Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden.
Section of Hematology and Coagulation, Sahlgrenska University Hospital, Gothenburg, Sweden; Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden.
Department of Hematology, Uppsala University Hospital, Umeå, Sweden.
Department of Hematology, Cancer Centre, University Hospital, Umeå, Sweden.
Show others and affiliations
2017 (English)In: Haematologica, ISSN 0390-6078, E-ISSN 1592-8721, Vol. 102, no 10, 1683-1690 p.Article in journal (Refereed) Published
Abstract [en]

A plastic anemia is a rare life-threatening disease. However, since the introduction of immunosuppressive therapy and allogeneic stem cell transplantation, the outcome has improved considerably, and the 5-year survival is reported to be 70-80% in selected patient cohorts. Yet, contemporary population-based data on incidence and survival are lacking. We performed a national retrospective study to determine the incidence, treatment, and survival of patients with aplastic anemia diagnosed in Sweden from 2000-2011. Patients were included via the National Patient Registry, and diagnosed according to the Camitta criteria. In total, 257 confirmed cases were identified, with an overall incidence of 2.35 (95% CI: 2.06-2.64) cases per million inhabitants per year. Median age was 60 years (range: 2-92), and median follow up was 76 (0-193) months. Primary treatments included immunosuppressive therapy (63%), allogenic stem cell transplantation (10%), or single-agent cyclosporine/no specific therapy (27%). The 5-year survival was 90.7% in patients aged 0-18 years, 90.5% in patients aged 19-39 years, 70.7% in patients aged 40-59 years, and 38.1% in patients aged ≥60 years. Multivariate analysis showed that age (both 40-59 and ≥60 age groups), very severe aplastic anemia and single-agent cyclosporine/no specific therapy were independent risk factors for inferior survival. In conclusion, younger aplastic anemia patients experience a very good long-term survival, while that of patients ≥60 years in particular remains poor. Apparently, the challenge today is to improve the management of older aplastic anemia patients, and prospective studies to address this medical need are warranted.

Place, publisher, year, edition, pages
Pavia, Italy: Ferrata Storti Foundation, 2017. Vol. 102, no 10, 1683-1690 p.
National Category
Hematology
Identifiers
URN: urn:nbn:se:oru:diva-61464DOI: 10.3324/haematol.2017.169862ISI: 000411964200020PubMedID: 28751565Scopus ID: 2-s2.0-85030308835OAI: oai:DiVA.org:oru-61464DiVA: diva2:1149042
Note

Funding Agencies:

ALF Vastra Gotaland

Gothenburg Medical Society 

Alexion Sweden 

Available from: 2017-10-13 Created: 2017-10-13 Last updated: 2017-11-27Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Authority records BETA

Uggla, Bertil

Search in DiVA

By author/editor
Uggla, Bertil
By organisation
School of Medical Sciences
In the same journal
Haematologica
Hematology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 28 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf